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Abstract
Purpose
COVID-19 infection resulting from severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began to spread across the globe in early 2020. Patients with hematologic
malignancies are supposed to have an increased risk of mortality from coronavirus disease
of 2019 (COVID-19) infection. From Pakistan, we report the analysis of the outcome and
interaction between patient demographics and tumor subtype and COVID-19 infection and
hematological malignancy.

Patients and methods
This multicenter, retrospective study included adult patients with a history of histologically
proven hematological malignancies who were tested positive for COVID-19 via PCR presented at the oncology department of 5 tertiary care hospitals in Pakistan from February to
August 2020. A patient with any known hematological malignancy who was positive for
COVID-19 on RT-PCR, was included in the study. Chi-square test and Cox-regression hazard regression model was applied considering p � 0.05 significant.

Results
A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out
of which 82 (76.64%) were alive, and 25 (23.36%) were dead. The significant hematological
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malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%), respectively. The majority of the patients in both the dead and alive group were on active treatment
for hematological malignancy while they came positive for COVID-19 [21 (84.00%) & 48
(58.54%) p 0.020]. All patients in the dead group were admitted to the hospital 25
(100.00%), and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5)
number of days. Among those who had contact exposure, the hazard of survival or death in
patients with hematological malignancies and COVID-19 positive was 2.18 (CI: 1.90–4.44)
times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared to no exposure
history (p 0.001).

Conclusion
Taken together, this data supports the emerging consensus that patients with hematologic
malignancies experience significant morbidity and mortality resulting from COVID-19
infection.

Introduction
The SARS-Cov-2 or COVID-19, known as novel coronavirus, has become a global threat and
healthcare concern. Since its outbreak in China at the end of 2019, the pandemic has affected
more than 100 million people worldwide [1]. Although the outbreak is likely to have started
from a zoonotic spread, it soon became apparent that person-to-person transmission occurs
mainly through respiratory droplets and direct contact with a diseased person or indirect contact with fomites in the environment [2, 3]. Many people have mild symptoms. In contrast,
others have no symptoms at all but still, actively carry and transmit the virus. However, some
do develop severe symptoms such as respiratory failure, cytokine release syndrome, and multiorgan failure [4].
Since COVID-19 began to spread across the globe in early 2020, patients with comorbidities
and cancer are more susceptible to marked complications of viral infection. Cancer patients
are more prone to increased risk of infections than individuals without cancer because of
immunosuppression by the malignancy itself and anticancer treatments, such as chemotherapy or surgery [5, 6] and have a poorer prognosis. Cao et al. have reported that patients with
metastatic disease, hematological malignancy, or lung cancer are at particularly high risk of
severe complications, requiring intensive care unit (ICU) admission, invasive mechanical ventilation, and even death. Furthermore, active treatment such as surgery and immunotherapy is
associated with a significantly increased risk (hazard ratios of 6.22 and 4.82) respectively, for
poor outcomes [7], Zhang et al. reported a higher rate of adverse events (53.6%) and mortality
(28.6%) in those who had their last anti-tumor treatment within 14 days of the infection
(HR = 4.079, 95% CI 1.086–15.322, P = 0.037). We do know that patients with hematological
malignancies can have an underlying immune dysfunction and are vulnerable to viral and
other infections [9]. Additionally, treatments which include cytotoxic agents, immunomodulators, hematopoietic stem cell transplantation, and chimeric antigen receptor T-cell therapy,
are profoundly immunosuppressive. In addition, patients with hematologic malignancies have
multiple risk factors of particular concern in the context of COVID-19 infection such as
advanced age, underlying or treatment-induced comorbid illnesses like hypertension and
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diabetes, and chronic lymphopenia. These factors make this patient population particularly
susceptible to an adverse outcome.
Public health measures are universally instituted to control the disease spread and aim to
decrease preventable hospital admissions. In addition, it is recommended that patients receiving anticancer treatment should have vigorous screening for COVID-19 [8]. However, cancer
care encompasses a diverse array of primary tumor types and stages, affecting all age groups of
patients, with different prognosis and outcomes. Therefore, labeling all patients with cancer as
susceptible to COVID-19 is probably neither reasonable nor informative.
For patients with hematologic malignancies, the overall risk of morbidity and mortality
resulting from COVID-19 infection, as well as how this risk varies as a function of age, disease
status, type of malignancy, and cancer therapy is being studied [9]. However, data from lowand middle-income countries is sparse. It is hypothesized that lower rates of testing and contact tracing and dearth of medical facilities adequately equipped to manage complicated covid
infections can potentially result in higher morbidity and mortality in this high-risk population.
From Pakistan, we report the analysis of the interaction between patient demographics and
tumor subtype and COVID-19 infection and outcomes in patients with hematological malignancy. This is a multicenter analysis from five tertiary care hospitals in Pakistan, all of whom
have an established cancer center.

Materials and methods
We retrospectively collected data on all the patients with a history of histologically proven
hematological malignancies that tested positive for COVID-19 by RT-PCR and present at the
oncology department of 5 tertiary care hospitals in Pakistan: Aga Khan University Hospital
Karachi, Armed Forces Bone Marrow Transplant Centre Rawalpindi, Hameed Latif Hospital
Lahore, Shifa International Hospital Islamabad, and Shaukat Khanum Memorial Cancer Hospital Lahore from February to August 2020. Data was collected using a standard Performa
developed for this study. Demographic, clinical, treatment, and laboratory data and serial samples for viral RNA detection were extracted from the medical records of 107 patients.
Patient with any known hematological malignancy who was positive for COVID-1f on
RT-PCR was included in the study. Patients with a clinical or radiological diagnosis of
COVID-19 without a positive RT-PCR test, were not included in this analysis.

Operational definition
Leukemia is cancer of the body’s blood-forming tissues, including the bone marrow and the
lymphatic system [10].
Lymphoma is a cancer of the lymphatic system, which is part of the body’s germ-fighting
network. The lymphatic system includes the lymph nodes (lymph glands), spleen, thymus
gland, and bone marrow [11].
Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone
marrow and are an important part of the immune system [12].
Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming
cells in the bone marrow become abnormal. This leads to low numbers of one or more types of
blood cells [12].

Clinical classification of suspected or confirmed COVID-19 patients in
Pakistan
Asymptomatic SARS CoV-2 infection but with no symptoms. Some asymptomatic patients
may be pre-symptomatic if tested early (e.g., as part of contact tracing) [13].
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Non-Severe Oxygen saturation of 94% or greater and respiratory rate of less than 25
breaths/minute [14].
Severe Oxygen saturation < 94% and respiratory rate greater than 25 breaths/minute.
Oxygen saturation is maintained by nasal cannulation or simple facemask, no need for
non-invasive or invasive mechanical ventilation [14].
Critical Respiratory compromise severe enough requiring invasive and non-invasive
mechanical ventilation [13].

Variables
Age, Sex, Hospital, Co-morbidities, Hematological malignancy, treatment, chemotherapy,
COVID-19 exposure, presenting complaint, hospital admission, COVID-19 status at death or
discharge were the covariates.

Outcome
Mortality—the number of deaths in patients with hematological malignancy diagnosed with
COVID-19 infection.

Statistical analysis
The data was entered and analyzed by using STATA version 16. Calculated medians for all
continuous skewed variables. The normality of data was checked through density plots—frequencies with percentages for categorical variables. A Chi-square test was performed to check
the association between the covariates and mortality. For survival analysis, a multivariable
Cox-regression hazard regression model was applied, and the Kaplan Meir survival curve was
used to check the overall survival. P-value �0.05 was considered significant.

Ethical approval
Ethical approval was obtained from the Ethical Review Committee of the Aga Khan University
Hospital, Karachi, Pakistan. Data were retrospectively collected through chart review, so there
was no need for the informed written consent.

Results
Baseline characteristics
A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out
of which 82 (76.64%) were alive, and 25 (23.36%) were dead. Among the dead, 12 (48.00%) of
the participants were greater than 50 years of age (p 0.027). Most of the participants were
males in both the dead and alive group [18 (72.00%) & 54 (68.85%)]. Hypertension was the
common comorbidity in both groups [8 (32.00%) & 8 (9.76%) p 0.021]. The significant hematological malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%),
respectively (Table 1). The majority of the patients in both the dead and alive group were on
active treatment for hematological malignancy while they came positive for COVID-19 [21
(84.00%) & 48 (58.54%) p 0.020]. IV chemotherapy was the common treatment 15 (71.43%)
from the dead group, and 29 (61.70%) in the alive group received IV chemotherapy moreover
Idarubicin + cytarabine was the common IV chemo-regimen given to patients in both groups
[5 (23.81%) & 5 (12.20%)] (Table 2). The presenting complaint in patients with hematological
malignancies who catch COVID-19 among the dead group were fever (52.00%) followed by
respiratory symptoms 11 (44.00%). However, in the alive group, 18 (21.95%) were asymptomatic, 22 (26.83) presented with fever, 33 (40.24%) presented with respiratory symptoms (p
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Table 1. Baseline and clinical characteristics of patients with hematological malignancies and COVID-19 stratified on the outcome (n = 107).
Characteristic

Outcome n (%)

P-value

Dead [25 (23.36%)]

Alive [82 (76.64%)]

7 (28.00)

34 (41.46)

31–50

6 (24.00)

31 (37.80)

>50

12 (48.00)

17 (20.73)

Male

18 (72.00)

54 (68.85)

Female

7 (28.00)

28 (34.15)

AKUH

8 (32.00)

9 (10.98)

SKMCH

6 (24.00)

48 (58.54)

Shifa Hospital

6 (24.00)

16 (19.51)

AFBMTC

5 (20.00)

7 (8.54)

HLH

0 (0.00)

2 (2.44)

None

8 (32.00)

50 (60.98)
8 (9.76)

Age (years)
10–30

0.027

Sex

0.566

Hospital

0.012

Co-morbidities

0.021

HTN

8 (32.00)

Diabetes

2 (8.00)

7 (8.54)

Other

7 (28.00)

17 (20.73)

ALL

3 (12.00)

11 (13.41)

Malignancy

0.222

AML

7 (28.00)

6 (7.32)

CML

1 (4.00)

4 (4.88)

CLL

2 (8.00)

5 (6.10)

Hodgkins

2 (8.00)

17 (20.73)

B- cell lymphoma

4 (16.00)

21 (25.61)

T- cell lymphoma

1 (4.00)

3 (3.66)

Others

5 (20.00)

15 (18.29)

https://doi.org/10.1371/journal.pone.0267139.t001

0.029). There was a contact exposure in 3 (12.00%) and travel history in 8 (32.00%) of patients
in the dead group while 13 (15.85%) had contact exposure and 9 (10.98%) had travel history
among the alive group (p 0.042). All patients in the dead group were admitted in the hospital
25 (100.00%) and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5)
number of days while 24 (29.27%) alive patients were admitted to hospital and only 4 (4.88%)
admitted in ICU (p <0.001). At discharge or death, 4 (16.00%) dead patients were COVID
positive, and 30 (36.59) alive patients were positive (p 0.008) (Table 3).

Overall survival and multivariable regression
The median overall survival among patients with hematological malignancies and COVID-19
positive was 33 (IQR 15–60) days (Fig 1). Upon applying multivariable Cox-proportional hazard
regression, age (categorical), malignancy treatment, COVID-19 exposure, and COVID-19 status
at death or discharge were significant (Table 4). The hazard ratio of survival or death in patients
with hematological malignancies and COVID-19 positive in the age group 10–30 years was 1.81
times (CI: 1.40–2.72) and 1.22 times among age group 31–50 years (CI: 1.14–2.00) compared to
age greater than 50 years (p 0.019). The hazard ratio of survival or death in patients with hematological malignancies and COVID-19 positive in patients receiving IV chemotherapy was 1.51
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Table 2. Treatment and management of patients with hematological malignancies and COVID-19 stratified on outcome (n = 107).
Characteristic

Outcome

P-value

Dead [25 (23.36%)]

Alive [82 (76.64%)]

Yes

21 (84.00)

48 (58.54)

No

4 (16.00)

34 (41.46)

Chemoimmunotherapy

5 (23.81)

13 (27.66)

IV chemotherapy

Active treatment

0.020

Treatment

0.797
15 (71.43)

29 (61.70)

TKI

1 (4.76)

4 (8.51)

Radiation

0 (0.00)

1 (2.13)

2 (9.52)

7 (17.07)

Chemo regimen
R-CHOP

0.551

R- Bendamustine

0 (0.00)

2 (4.88)

R-ICE

1 (4.76)

2 (4.88)

R-CEOP

0 (0.00)

1 (2.44)

R-EPOCH

1 (4.76)

1 (2.44)

Rituximab

1 (4.76)

0 (0.00)

CVP

0 (0.00)

1 (2.44)

Idarubicin + cytarabine

5 (23.81)

5 (12.20)

BFM protocol

1 (4.76)

3 (7.32)

HyperCVAD

4 (19.05)

5 (12.20)

ABVD

3 (14.29)

7 (17.07)

Bendamustine

0 (0.00)

2 (4.88)

VRD

3 (14.29)

1 (2.33)

Cyclophoshamide +bortezomib

0 (0.00)

2 (4.88)

Lenalodomide + carfilzomib

0 (0.00)

2 (4.88)

https://doi.org/10.1371/journal.pone.0267139.t002

(CI: 1.26–2.47) times and 1.46 times who received chemoimmunotherapy (CI: 1.30–2.39) compared to those who received TKI (p 0.031). Among those who had contact exposure, the hazard
of survival or death in patients with hematological malignancies and COVID-19 positive was
2.18 (CI: 1.90–4.44) times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared
to no exposure history (p 0.001). Moreover, the hazards were higher in patients who did not test
for COVID or were positive at discharge or death 2.28 (CI: 1.43–5.63) and 3.41 (CI: 2.12–6.38)
compared to those who were negative at discharge or death (p 0.001).

Discussion
Worldwide, healthcare systems are in an uphill task of dealing with the COVID-19 pandemic,
a situation that is going to remain a challenge to all clinicians. The incidence of COVID-19
and outcomes in cancer patients is a topic of great interest. It is evident now that the COVID19 will be a global health care issue for the foreseeable future, and it is imperative that clinicians
understand the complexity of presentations and outcomes of patients with concomitant health
issues that make them vulnerable to severe complications. Our study has mainly focused on
outcomes of COVID-19 with hematological malignancies in a resource-constrained environment, and it’s the first multicenter analysis from Pakistan.
American Society for Hematology (ASH) Research Collaborative COVID-19 Registry analysis states that patients with hematologic malignancies have higher mortality resulting from
COVID-19 than in the general population. They reported an overall mortality of 28%,
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Table 3. COVID-19 exposure and status at death/discharge among hematological malignancies patients stratified on outcome (n = 107).
Characteristic

Outcome

P-value

Dead [25 (23.36%)]

Alive [82 (76.64%)]

Fever

13 (52.00)

22 (26.83)

Respiratory symptoms

11 (44.00)

33 (40.24)

Presenting complaint

0.029

GI symptoms

1 (4.00)

4 (4.88)

Other

0 (0.00)

5 (6.10)

Asymptomatic

0 (0.00)

18 (21.95)

No

14 (56.00)

60 (73.17)

Contact exposure

3 (12.00)

13 (15.85)

Travel

8 (32.00)

9 (10.98)

No

0 (0.00)

58 (70.73)

Yes

25 (100.00)

24 (29.27)

0 (0.00)

58 (70.73)
16 (19.51)

COVID-19 exposure

0.042

Hospital admission

<0.001

In hospital stay
No admission

<0.001

Ward

5 (20.00)

SCU

6 (24.00)

4 (4.88)

ICU

14 (56.00)

4 (4.88)
0.003�

If yes, Number of days
(Median, IQR)

11 (6–16.5)

0 (0–4)

25 (0.00)

2 (2.44)

Recovered & discharged
No

<0.001

Yes

0 (0.00)

35 (42.68)

Home isolation

0 (0.00)

45 (54.88)

Not done

9 (36.00)

37 (45.12)

Negative

12 (48.00)

15 (18.29)

Positive

4 (16.00)

30 (36.59)

COVID status at death/discharge

0.008

https://doi.org/10.1371/journal.pone.0267139.t003

increasing to 42% in patients with moderate to severe infection [15–17]. However, in the general population, it ranges from 9–29.6%. In the white Hispanic group, the mortality was less
than 10%, while in Black and Hispanic groups, it was less than 30% in the general population
[18]. Recently published study from Italy stated mortality of 37% patients with hematological
malignancy and COVID-19, with higher risk amongst those with older age, progressive disease,
or severe infection [19, 20]. Another multicenter study, analyzing outcomes in cancer patients
from China reported mortality of 20%, with 41% mortality in the 22 patients with hematologic
malignancies [21]. UK Myeloma Forum published their results of 75 patients with COVID-19
and multiple myeloma, with mortality of 55% [22, 23]. In our study, the overall mortality mirrors the data of these studies with an overall mortality of 23% and increasing to approximately
51% in the hospitalized patients and 86% in ICU patients. 50% of deaths were seen in patients
younger than 50 years. This is most likely due to the fact that approximately 70% of our patients
were in that age group. Therefore, this is likely over-represented. It was interesting to note the
relatively low numbers of patients of older age admitted to the hospital in our cohort. It could
be hypothesized that treatment was deferred for the older patients with multiple co-morbidities
in the initial months of the pandemic if they had a relatively stable clinical course. However, it
would be interesting to study the outcomes of patients who had their treatment deferred.
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Fig 1. Graph representing overall survival in patients with hematological malignancies and COVID-19.
https://doi.org/10.1371/journal.pone.0267139.g001

Several other findings from our cohort are noteworthy. We analyzed the demographics of
COVID-19 patients with hematological malignancy and explored the effect of cytotoxic chemotherapy and various chemoimmunotherapy and targeted treatments on the trajectory of
COVID-19. The incidence of COVID-19 was found to be more frequent in acute leukemias
(29%), followed by non-Hodgkin’s lymphoma (27%) and Hodgkin’s lymphoma (18%) [24].
Furthermore, an increase in mortality has been reported in myeloid malignancies (MDS/
AML/MPN) than lymphoid neoplasms (NHL/CLL/ALL/MM/HL) (43% vs. 35%) [25, 26],
which is similar to that seen in our study population. The majority of our study patients were
on active treatment and reported a mortality rate of 19.6%, in contrast to 10% among patients
on surveillance. Interestingly a higher mortality rate (14%) was seen in patients receiving chemotherapy alone compared to a 4.6% receiving chemoimmunotherapy.
The most common COVID-19–specific therapies in our dataset were symptomatic treatment
with steroids and anticoagulation, tocilizumab (6.5%), remdesivir (2.8%), hydroxychloroquine
(3.7%). The use of tocilizumab and remdesivir in our cohort as low compared to other studies
[10]. One reason is that our data collection started in the early days of the pandemic when these
drugs were not used regularly. Additionally, the availability of the drugs was sparse until the mid
of 2020. Remdisivir was given emergency use authorization in May 2020 and gained full FDA
approval in October 2020. It only then has this drug become widely available for use.
Morbidity rates from COVID-19 in patients with cancer admitted to the hospital are high, particularly in older patients and those with hematological malignancies. But not all cancer patients
are affected equally. These findings allow clinicians to risk-stratify their patients; whether symptomatic or not, and make decisions on social isolation and shielding at appropriate levels. Our
data and many other studies demonstrate that patients with hematological malignancies,
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Table 4. Univariate and multivariable Cox-proportional hazard model reporting crude and adjusted ratios (n = 107).
Characteristic

Crude HR (95% CI)

p-value

Adjusted HR (95% CI)

p-value

Age (years)
>50

1

10–30

1.91 (1.84–2.37)

31–50

1.17 (1.03–1.56)

1
0.081�

1.81 (1.40–2.72)

0.019

1.22 (1.14–2.00)

Sex
Female
Male

1

0.107�

-

-

0.596

-

-

0.084�

1.51 (1.26–2.47)

1.84 (1.38–3.05)

Active treatment
Yes

1

No

1.19 (0.61–2.33)

Treatment
TKI

1

IV chemotherapy

1.19 (1.05–2.85)

Chemoimmunotherapy

1.36 (1.10–3.50)

1
0.031

1.46 (1.30–2.69)

COVID-19 exposure
No

1

Contact exposure

1.49 (1.19–3.17)

Travel

1.77 (1.61–5.12)

1
0.058�

2.18 (1.90–4.44)

0.001

3.10 (2.73–4.60)

Hospital admission
No

1

Yes

1.16 (0.62–2.20)

0.628

-

0.024�

2.28 (1.43–5.63)

-

COVID status at death/discharge
Negative

1

Not done

1.80 (1.49–2.38)

Positive

1.88 (1.58–4.16)

1
0.001

3.41 (2.12–6.38)

https://doi.org/10.1371/journal.pone.0267139.t004

particularly acute leukemias, are at high risk for severe COVID-19 infection and mortality. Therefore, preemptive testing, early recognition of infections, and prompt management at a facility
with expertise to manage complications are paramount. In addition, protective measures such as
universal masks, social distancing, and shielding this susceptible population from COVID-19
exposure are mandatory. Many sites have implemented telemedicine to on-site physical distancing, and these practices should continue if COVID-19 prevalence remains high.
Our study has some limitations. Our analyses are based on patients with hematological
malignancy who sought help from centers receiving their treatment. Therefore, this cohort did
not capture the outcomes of patients who presented for management at a different hospital.
This is particularly true for patients who live in cities or towns and most likely obtained treatment closer to home. Also, we likely missed patients on long-term follow-up who approached
their local general physician (GP) or hospital. We, too, were unable to capture asymptomatic
patients and found to have COVID-19 positive on screening. In addition, patients on hospice
care were not reported or included in this study. Therefore, it is impossible to accurately quantify the burden of infection in patients with hematological malignancy.
Nonetheless, this dataset provides a glimpse of outcomes of patients who presented to a tertiary care hospital in Pakistan where both states of art management for covid infection and the
primary malignancy was available. The majority of our patients were on active treatment, and
these results help prognosticate; patients who require intensive care carry a very grim prognosis. Data such as ours are especially important in formulating country/region region-specific
guidelines regarding the management of covid infections in a specific subset of patients. This
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is important in guiding management decisions when resources are limited and medical care is
not covered by private insurance.
The expertise in managing COVID-19 infection has evolved over the last year. Early use of
dexamethasone, remdesivir, and anticoagulation has improved outcomes.

Conclusion
In summary, this study of patients with hematological malignancy and COVID-19 accentuates
several significant considerations for clinical care and emphasizes the urgent need for more
data. Longer-term follow-up and larger sample sizes are needed to understand the effect of
SARS-CoV-2 on outcomes in patients with hematological malignancy.
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